CORE--VIROLOGY CORE LABORATORY

艾滋病是一种病毒性疾病，临床进展与 增加了病毒负担。对体内HIV-1水平的准确评估将是 对监测治疗效果至关重要。HIV-1的复制活性 现在可以通过常规免疫分析在一定程度上确定患者的 血清中P24核心蛋白及病毒分离。这两种病毒学 检测在我们实验室已经使用了很多年，而这一专业知识 自1984年以来，我们的出版物都很好地记录了这一点。另外，我们是 第一个开发定量培养法，可以确定 HIV-1在血浆和外周血单核细胞中的感染滴度 病人的细胞。此外，我们还利用了这些终点稀释 证明存在或不存在体内有效性的检测方法 抗病毒药物。在过去的两年里，中国HIV-1DNA的定量 本实验室还实现了临床标本的聚合酶链式反应。 这种定量的聚合酶链式反应技术能够检测波动 在我们遇到的HIV-1病毒携带者中。我们现在建议表演 P24抗原检测和HIV-1培养作为临床的常规服务 在纽约大学ACTG进行的试验。在特定的临床情况下， 还将进行定量培养和聚合酶链式反应测试，以确定 新型治疗药物的抗病毒活性。

AIDS is a viral disease, and clinical progression is associated with increased viral burden. Accurate assessment of HIV-1 level in vivo will be critical for monitoring treatment efficacy. Replicative activity of HIV-1 in patients can now be determined to an extent by routine immunoassay for p24 core protein in serum and by virus isolation. both of these virologic tests have been used in our laboratory for many years, and this expertise is well documented by our publications since 1984. In addition, we were the first to develop quantitative cultures which can determine the infectious titers of HIV-1 in the plasma and peripheral blood mononuclear cells of patients. Furthermore, we have utilized these end-point-dilution assays to demonstrate the presence or absence of in vivo efficacy of antiviral agents. In the past two years, quantitation of HIV-1 DNA in clinical samples by PCR methods has also been achieved in our laboratory. This quantitative PCR technique has permitted the detection of fluctuations in HIV-1 load in the patients encountered by us. We now propose to perform p24 antigen assays and HIV-1 cultures as a routine service for the clinical trials conducted at the NYU ACTG. In select clinical situations, quantitative culture and PCR tests will also be done to determine the antiviral activity of new therapeutic agents.